Antibiotics and nano-antibiotics in treatment of lung infection: In management of COVID-19.

Antibiotics and nano-antibiotics in treatment of lung infection: In management of COVID-19.

Publication date: Sep 23, 2023

The world has witnessed the cruelty of COVID-19 disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The association of COVID-19 with other secondary and bacterial co-infections has tremendously contributed to lung infections. An increased probability of having a secondary lung infection was observed among the post-COVID patients. The treatment of antibiotics has ameliorated the mortality rate. However, the stewardship of antibiotic treatment was linked to increased organ failure. Therefore, the paper discusses the interactions between the virus and host through the ACE2 receptors that contribute to COVID-19 development. Furthermore, the paper provides an invaluable compendium history of SARS-CoV-2 genomic composition. It revolves around most classes of antibiotics used to treat COVID-19 disease and post-COVID lung infections with the complete mechanism. This binds with the exertion of the antibiotics for bacterial infection associated with COVID-19 patients and how beneficial and effective responses have been recorded for the treatment. The application of nanotechnology and possible approaches of nanomedicines is also discussed to its potential usage.

Concepts Keywords
Antibiotic Antibiotics
Complete COVID-19
Coronavirus Gram-negative bacteria
Nanotechnology Nanoparticles
Organ Pathogens


Type Source Name
disease MESH infection
disease MESH COVID-19
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH co-infections
disease VO organ
disease IDO host
disease IDO history
disease MESH bacterial infection
disease VO effective
disease VO Bacteria

Original Article

(Visited 1 times, 1 visits today)